Loss of Mdm4 Results in p53-Dependent Dilated Cardiomyopathy

Background— Although several loci for familial dilated cardiomyopathy (DCM) have been mapped, the origin of a large percentage of DCM remains unclear. Mdm2, a p53-negative regulator, protects cardiomyocytes from ischemic and reperfusion-induced cell death. Mdm4, a homolog of Mdm2, inhibits p53 activity in numerous cell types. It is unknown whether Mdm4 plays a role in the inhibition of p53 in fully differentiated tissues such as adult cardiomyocytes and whether this role is associated with DCM. Methods and Results— The conditional knockout of Mdm4 in the heart by use of cardiomyocyte-specific Cre (&agr;MyHC-Cre) allele does not result in any developmental defects. With time, however, mice with deletion of Mdm4 in the adult heart developed DCM and had a median survival of 234 days. More interestingly, the onset of DCM occurs significantly earlier in male mice than in female mice, which mimics human DCM disease. DCM in Mdm4 mutant mice was caused by loss of cardiomyocytes by apoptosis, and it was p53-dose dependent. Conclusion— Activity of p53 was inhibited by Mdm4 even in the fully differentiated cardiomyocyte. Elevated apoptosis mediated by the p53 pathway in cardiomyocytes may be a mechanism for DCM.

[1]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[2]  L. Qin,et al.  Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase* , 2006, Journal of Biological Chemistry.

[3]  L. Melton,et al.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. , 1989, Circulation.

[4]  P E Leaverton,et al.  Prevalence and mortality rate of congestive heart failure in the United States. , 1992, Journal of the American College of Cardiology.

[5]  A. Jochemsen,et al.  Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death , 2006, Cell Death and Differentiation.

[6]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[7]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[8]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[9]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[10]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[11]  G. Lozano,et al.  Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4 , 2006, Molecular and Cellular Biology.

[12]  E. Ehler,et al.  Cardiomyocyte Cytoskeleton and Myofibrillogenesis in Healthy and Diseased Heart , 2000, Heart Failure Reviews.

[13]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[14]  L. Mestroni,et al.  Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. , 1995, American journal of human genetics.

[15]  M. Keating,et al.  Mapping a cardiomyopathy locus to chromosome 3p22-p25. , 1996, The Journal of clinical investigation.

[16]  L. Field,et al.  Cardiomyocyte cell cycle regulation. , 2002, Circulation research.

[17]  David S. Park,et al.  Telencephalon‐specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development , 2002, The EMBO journal.

[18]  K. Chien,et al.  Complexity in simplicity: monogenic disorders and complex cardiomyopathies. , 1999, The Journal of clinical investigation.

[19]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .

[20]  S. Francoz,et al.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Rumyantsev,et al.  Interrelations of the proliferation and differentiation processes during cardiact myogenesis and regeneration. , 1977, International review of cytology.

[22]  Yolande F M Ramos,et al.  Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. , 2001, Cancer research.

[23]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[24]  R. Weinberg,et al.  Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.

[25]  G. Koch,et al.  Gender differences in survival in advanced heart failure. Insights from the FIRST study. , 1999, Circulation.

[26]  J. Otto,et al.  On the Physiological Importance of Endoproteolysis of CAAX Proteins , 2004, Journal of Biological Chemistry.

[27]  D. Fatkin,et al.  Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. , 2004, The Journal of clinical investigation.

[28]  H. Drexler,et al.  Clinical applications of stem cells for the heart. , 2005, Circulation research.

[29]  S. Thibodeau,et al.  Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. , 1998, Science.

[30]  A. Kong,et al.  A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1–1q1 , 1994, Nature Genetics.

[31]  Geng-Hung Liu,et al.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Towbin,et al.  Genetic heterogeneity in familial dilated cardiomyopathy. , 1995, Biochemical and molecular medicine.

[33]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[34]  B. A. French,et al.  Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. , 1997, The Journal of clinical investigation.

[35]  K. Helin,et al.  Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.

[36]  J. Towbin,et al.  Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. , 1995, Circulation.

[37]  Yolande F M Ramos,et al.  Comparative study of the p53-mdm2 and p53-MDMX interfaces , 1999, Oncogene.

[38]  R. Ramirez-Solis,et al.  mdmx is a negative regulator of p53 activity in vivo. , 2002, Cancer research.

[39]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[40]  C. Mummery.  Cardiology: Solace for the broken-hearted? , 2005, Nature.

[41]  G. Dorn,et al.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[43]  J H Patterson,et al.  Relation between gender, etiology and survival in patients with symptomatic heart failure. , 1996, Journal of the American College of Cardiology.

[44]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[45]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.